Drug intelligence / Profile preview

Vertigo Hennig

Development stage: Unknown
Lead developer: Henning Arzneimittel
Administration: Oral

Overview

Vertigo Hennig is a homeopathic complex preparation developed and marketed by HENNIG ARZNEIMITTEL for the treatment of dizziness (vertigo), particularly in elderly patients associated with cerebral vascular calcification. The product contains four natural active ingredients in specific homeopathic dilutions: *Anamirta cocculus* (D4), *Conium maculatum* (D3), *Ambra grisea* (D6), and *Petroleum rectificatum* (D8). As a homeopathic medicine, it does not target specific molecular pathways in a conventional pharmacological sense; instead, it is marketed to promote cerebral blood circulation and improve the processing of sensory information responsible for balance. It is available as an over-the-counter (OTC) tablet in Germany.

Brand names: Vertigo Hennig
Other names: HENNIG-Vertigo

Beyond the preview

Go deeper on Vertigo Hennig.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vertigo Hennig.

Explore the full profile